Prior authorization has been a healthcare sticking point for years.
Patients and providers criticize prior authorization (PA) for denying care and coverage. State and federal lawmakers target it, setting standards and policies for how health plans must operate, often without a deep understanding of the complexities of the issue. In response to the public and legislative pressure, many plans are reducing their reliance on PA.
UnitedHealthcare announced that it will cut PA requirements by 30% by the end of 2026, including some outpatient surgeries and diagnostic tests, as well as certain outpatient therapies and chiropractic care.
UnitedHealthcare's announcement is just the latest in a series of moves by plans to reduce their reliance on PA. In June 2025, industry organization AHIP committed to six PA reforms across commercial, Medicare Advantage and Medicaid managed care coverage, including reduced requirements and faster response times. Individual plans also have acted. AHIP reported earlier this year that major insurers had cut 11% of PAs (6.5 million).
While reducing PA will certainly eliminate some friction, and please patients and providers, blanket policies are seldom the solution to an issue this complex. Rather, this is an opportunity to take a smarter approach to PA, one that improves care and makes it smarter, fairer, and more efficient for all involved. One that treats PA as a tool for better care rather than a barrier.
The cost of poor prior authorization
There is no doubt that PA needs to improve. A process that started in the 1960s with the launch of Medicare has become far too cumbersome. Providers say it delays or prevents treatment, adds administrative costs, and overrides their clinical judgment. A 2026 AMA survey found an average of 40 requests per physician per week, taking 13 hours of physician and staff time.
Members become frustrated with their plans when approval isn't granted, often without explanation.
Plans counter that PA helps ensure appropriate care, block unnecessary or unsafe care, and control costs.
Despite all the heat surrounding this issue, there is room – and need – for compromise. Technology has made it possible for PA to be handled far more quickly than in the days of fax machines and phone calls. Both plans and providers also have access to science-backed policies that can better inform their decisions.
Rethinking prior authorization
It's important to understand that the problems with PA are not the fault of any single party. There needs to be improvement and mutual accountability on both sides in order to improve the process.
Plans owe providers and their members transparency in their policies and decision-making, consistent turnaround on claims, and fast, clear decisions. Providers owe plans accurate, evidence-based ordering and complete documentation. This is a precondition for any PA reform to actually work. Without mutual accountability, reducing mandatory PA checks just shifts risk around instead of removing it.
It's time to reset our idea of PA from a barrier to care or an indiscriminate way to control spending, to a tool for ensuring patients receive the right care at the right time for the right reason. It should guide and clear the way for timely, effective care.
Lab Benefit Management
An example of this can be found in lab benefit management (LBM), the governance of lab testing. Clinical testing is the most common medical procedure. Approximately 14 billion lab tests are performed annually, and the results inform 70% of healthcare decisions. However, because individual tests are generally inexpensive, they are not as scrutinized as other procedures. The result is that as much as 30% of testing is unnecessary or redundant, wasting billions of dollars and hindering care.
LBM tackles this problem by creating a science-backed set of policies for individual plans. It identifies the tests that offer clinical utility and validity and uses those findings to inform coverage decisions from plans and guide clinicians toward the most effective treatments.
However, creating accurate, science-based policies is only the first part of a comprehensive LBM program; the other half is implementing it. Much of the problem with PA is that it is reactive: a clinician submits a request; the plan may reject it for any number of reasons, and it comes back to a frustrated clinician and member, who must try to resolve the issue.
Here's a better way: An automated solution trained in plan-specific policies and coverage is integrated into providers' EHRs. It spots inaccurate or missing information in a PA request and flags it for the provider to correct before submission. Once the request is in order and meets the necessary criteria, the solution automatically approves it, removing uncertainty. It also lets the provider know whether the test or treatment is not covered for that patient or if the plan prefers an alternative. A provider can then decide whether to choose another, more appropriate test or proceed with further review by the health plan. In essence, the new process moves the appropriateness review farther upstream to the moment the provider enters an order for a test or procedure, saving time and resources.
There are other examples of innovation that link outcomes and PA. The new CMS Cell and Gene Therapy (CGT) Access Model, built around sickle cell disease gene therapies, involves government and drug manufacturers as well as plans and providers. CMS negotiates outcomes-based agreements directly with gene therapy manufacturers on behalf of states. The manufacturers provide guaranteed discounts and pay rebates back if the therapy doesn't deliver the promised clinical benefit. This shifts some of the financial risk from states to manufacturers.
This model works because of a safeguard baked into its design: strict upfront criteria to confirm which patients are truly eligible for the therapy. For a one-time, irreversible treatment costing millions of dollars, that kind of appropriateness review isn't a barrier to access — it's what makes access sustainable. The outcome-based rebates manufacturers and states are counting on only hold up if the therapy reaches the patients it's meant for. In that sense, the CGT model and smarter prior authorization share the same logic: verify appropriateness upfront, and both access and affordability take care of themselves.
The case for smarter prior authorization
The need for a better process to ensure high-quality, appropriate, and affordable care is made more urgent by the explosive growth of precision diagnostics and genetic medicine. These breakthroughs are transforming medicine, offering unprecedented accuracy in diagnostics and new treatments for diseases once thought incurable, but they are expensive and complex.
A process like the one described above will remove providers' doubt about which tests are appropriate, streamline the approval process, and enable patients to receive treatment faster.
As healthcare organizations and legislators consider PA reform, they should ask themselves if their plans only reduce risk and friction, or whether they truly improve the quality of the care that is being delivered to patients while insisting on accountability from all parties.
